Cancer diagnosis in primary care

Wilkinson, Anna N.

doi:10.46747/cfp.6704265

Cited by 79 publications

(102 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The inclusion of a greater number of women may be related to the 6- to 9-fold increased risk of hypothyroidism in women compared to men. Some of the factors that have been proposed are pregnancy, postpartum, menopause, and aging [ 8 , 32 , 33 ]. The development of future clinical studies that include patients with other causes of hypothyroidism, the evaluation of other associated factors for persistent fatigue, as well as the use of combination therapy with liothyronine, will allow overcoming these limitations and enrich the knowledge about fatigue in patients with hypothyroidism in order to improve their prognosis.…”

Section: Discussionmentioning

confidence: 99%

Severity of Fatigue and Its Relationship with TSH before and after Levothyroxine Replacement Therapy in Patients with Primary Hypothyroidism

et al. 2023

View full text Add to dashboard Cite

Background: Fatigue is a common symptom in hypothyroidism; however, the effect of levothyroxine on fatigue has been little studied. The aim of this study was to evaluate the effect of levothyroxine on fatigue in Latino patients with primary hypothyroidism, as well as the association of TSH and free T4 (FT4) with the severity and persistence of fatigue. Methods: A prospective study was performed in 92 patients with primary hypothyroidism. Fatigue severity scale (FSS) scores and clinical and biochemical characteristics before and at 6 months of levothyroxine were evaluated. Results: After 6 months of levothyroxine, a reduction in FSS (53 (47–57) vs. 36 (16–38); p = 0.001) and fatigue frequency (45.7% vs. 26.1%; p = 0.008) was evident. Both before and after 6 months of levothyroxine, there was a positive correlation of the FSS score with TSH and a negative correlation with FT4. Persistent fatigue was associated with a pretreatment FSS score (r = 0.75; p = 0.001) and diabetes (r = 0.40; p = 0.001). An FSS > 34 (RR 3.9 (95% CI 1.43–10.73; p = 0.008)), an FSS > 36 (RR 3.23 (95% CI 1.21–8.6; p = 0.019)), and diabetes (RR 5.7 (95% CI 1.25–9.6; p = 0.024)) before treatment were risk factors for persistent fatigue. Conclusions: Levothyroxine improved fatigue in most patients. Diabetes and an FSS score >34 or >36 before treatment were risk factors for persistent fatigue.

show abstract

Section: Discussionmentioning

confidence: 99%

Severity of Fatigue and Its Relationship with TSH before and after Levothyroxine Replacement Therapy in Patients with Primary Hypothyroidism

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Common etiologies include Candidiasis, Trichomoniasis, Bacterial Vaginosis, gonorrhea, chlamydia, and herpes simplex (Table 2). 19 Vaginal discharge can be little or no discharge at times. If the discharge is present, curd-like without or with minimal odor.…”

Section: Clinical History and Examinationmentioning

confidence: 99%

Vulvovaginal candidiasis: Epidemiology, treatment and prevention strategies

Seth¹,

Gandhi

Purandare³

et al. 2022

IJOGR

View full text Add to dashboard Cite

Vulvovaginal candidiasis (VVC) is a commonly encountered clinical condition. At least three-fourth women experience one episode of VVC in their lifetime. In India, the prevalence of VVC is 10 to 35%. Laboratory methods often supplement clinical diagnosis. VVC should be confirmed with culture and other investigative techniques, especially in complicated and recurrent cases. Topical and intravaginal azoles remain the mainstay of therapy. In women who have predisposing risk factors or develop recurrent VVC, oral antifungal agents are used. Topical steroids may be used in women having vulvar symptoms along with pruritus. Pregnancy is a significant risk factor. Intravaginal azoles remain the standard of treatment and can be offered from the second trimester onwards. The emergence of non-albicans species has caused difficulties in the management of VVCs. Thus, all women with vaginal discharge should be correctly diagnosed to tailor the therapy.

show abstract

“…Among them, IBS-D is the most common one with a proportion of nearly 60% in IBS according to a cross-sectional survey [4]. Although IBS-D affects patients' quality of life and brings huge financial burden to health system, the management is still a great challenge [5,6].…”

Section: Background and Rationale {6a}mentioning

confidence: 99%

The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial

Bai

Zeng

Long

et al. 2020

Trials

View full text Add to dashboard Cite

Background Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders characterized by recurrent abdominal pain associated with defecation or a change in bowel habits. Leading to significant negative effect on patients’ quality of life and huge financial burden to health system, the management of IBS is a great challenge. Probiotics are considered as an effective therapy; however, in a lack of high-quality evidence of efficacy, no strain- and dose-specific probiotics were recommended in clinical guidelines. This study aims to evaluate the efficacy of the Bifidobacterium quadruple viable tablet in the treatment of IBS-D. Methods/design A multicenter randomized controlled trial will be performed in fourteen hospitals. A total of three hundred patients who fulfill the eligibility criteria will be stratified divided into an experimental group and a control group randomly in a ratio of 1:1. The experimental group is treated with the Bifidobacterium quadruple viable tablet while the control group is treated with placebo. All the patients will receive a 4-week treatment and a 2-week follow-up. The primary outcome is the effectiveness in improving abdominal pain and stool consistency; the secondary outcome includes evaluation of overall symptom relief, frequency of defecation, bloating, urgency of defecation, remedial medication, score of IBS-QOL, and changes of microbiota and metabonomics. Physical examination, vital signs, laboratory tests, adverse events, and concomitant medication will be taken into account for intervention safety assessment during the trial. Discussion This multicenter randomized controlled trial may provide high-quality evidence on the efficacy of the Bifidobacterium quadruple viable tablet for IBS-D on both physical and mental dimensions in China. To fill the gap of previous probiotic intervention studies, in addition, this study will also present safety assessment which will be a significant emphasis. Trial registration ChiCTR1800017721. Registered on 10 August 2018.

show abstract

Cancer diagnosis in primary care

Cited by 79 publications

References 10 publications

Severity of Fatigue and Its Relationship with TSH before and after Levothyroxine Replacement Therapy in Patients with Primary Hypothyroidism

Severity of Fatigue and Its Relationship with TSH before and after Levothyroxine Replacement Therapy in Patients with Primary Hypothyroidism

Vulvovaginal candidiasis: Epidemiology, treatment and prevention strategies

The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial

Contact Info

Product

Resources

About